Candidemia clinical trials at UCLA
1 research study open to eligible people
Showing trials for
Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation
open to eligible people ages 18 years and up
The purpose of this pivotal study is to determine if intravenous Rezafungin is efficacious and safe in the prevention of invasive fungal diseases when compared to the standard antimicrobial regimen.
Los Angeles, California and other locations
Our lead scientists for Candidemia research studies include Drew J. Winston, MD.
Last updated: